Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients

International Journal of Clinical Pharmacy

Volumn 37, Issue 5, 2015, Pages 865-872

  Quesada, Pedro Rodríguez ^a   Esteban, Laura López ^a   García, Jimena Ramón ^a   Sánchez, Rocío Vázquez ^a   García, Teresa Molina ^a   Alonso Vega, Gabriel Gaspar ^a   Ferrández, Javier Sánchez Rubio ^a  

^a HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

Author keywords

HAART; HIV; Renal impairment; Tenofovir

Indexed keywords

ATAZANAVIR; CREATININE; DARUNAVIR; EFAVIRENZ; LOPINAVIR; NEVIRAPINE; RALTEGRAVIR; RILPIVIRINE; TENOFOVIR DISOPROXIL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; TENOFOVIR;

ADULT; AGE; ARTICLE; CARDIOVASCULAR DISEASE; COMORBIDITY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEPATITIS B; HEPATITIS C; HOSPITAL BED CAPACITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INCIDENCE; KIDNEY DISEASE; LOGISTIC REGRESSION ANALYSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SPAIN; SUBSTANCE ABUSE; TREATMENT DURATION; UNIVARIATE ANALYSIS; UNIVERSITY HOSPITAL; ADVERSE EFFECTS; CHEMICALLY INDUCED; DRUG EFFECTS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; RENAL INSUFFICIENCY;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; RISK FACTORS; SPAIN; TENOFOVIR;

EID: 84943197938     PISSN: 22107703     EISSN: 22107711     Source Type: Journal    
DOI: 10.1007/s11096-015-0132-1     Document Type: Article

References (48)

1. Kilmarx PH. Global epidemiology of HIV. Curr Opin HIV AIDS. 2009;4(4):240–6.
2. Lee SH, Kim KH, Lee SG, Chen DH, Jung DS, Moon CS, et al. Trends of mortality and cause of death among HIV-infected patients in Korea, 1990–2011. J Korean Med Sci. 2013;28(1):67–73.
3. Chowers MY, Gottesman BS, Leibovici L, Pielmeier U, Andreassen S, Paul M. Reporting of adverse events in randomized controlled trials of highly active antiretroviral therapy: systematic review. J Antimicrob Chemother. 2009;64(2):239–50.
4. Heath KV, Singer J, O’Shaughnessy MV, Montaner JSG, Hogg RS. Intentional nonadherence due to adverse symptoms associated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31(2):211–7.
5. d’Arminio Monforte A, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, et al. Insights into the reasons for discontinuation of the first highly active antirretroviral therapy (HAART) regimen in a cohort of antirretroviral naïve patients. AIDS. 2000;14(5):499–507.
6. Ammassari A, Murri R, Pezzotti P, Trotta MP, Ravasio L, De Longis P, et al. Self reported symptoms and medications side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr. 2001;28(5):445–9.
7. Martín MT, del Cacho E, López E, Codina C, Tuset M, de Lazzari E, et al. Adverse side effects of antiretroviral therapy: relationship between patients’ perception and adherence. Med Clin (Barc). 2007;129(4):127–33.
8. Schwartz EJ, Szczech LA, Ross MJ, Klotman ME, Winston JA, Klotman PE. HAART and the epidemic of HIV end stage renal disease. J Am Soc Nephrol. 2005;16:2412–20.
9. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [Internet]. Department of Health and Human Services; 2014 [cited 2014 May 22]. http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf.
10. ® EPAR_Product Information [Internet]. European Medicines Agency; 2014 [cited 2014 Mar 17]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/human/000419/WC500051737.pdf.
11. Shepp DH, Curtis S, Rooney JF. Causes and consequences of hypokalemia in patients on tenofovir disoproxil fumarate. AIDS. 2007;21(11):1479–81.
12. Jafari A, Khalili H, Dashti-Khavidaki S. Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention. Eur J Clin Pharmacol. 2014;70(9):1029–40.
13. Calza L, Trapani F, Salvadori C, Magistrelli E, Manfredi R, Colangeli V, et al. Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir. Scand J Infect Dis. 2013;45(2):147–54.
14. Bonjoch A, Echeverría P, Perez-Alvarez N, Puig J, Estany C, Clotet B, et al. High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy. Antiviral Res. 2012;96(1):65–9.
15. Lai S, Mariotti A, Lai C, Testorio M, Carta M, Innico G et al. Tenofovir-Related Nephropathies in HIV-Infected Patients. Curr Vasc Pharmacol. 2014 [Epub ahead of print].
16. Monteiro N, Branco M, Peres S, Borges F, Mansinho K. The impact of tenofovir disoproxil fumarate on kidney function: four-year data from the HIV-infected outpatient cohort. J Int AIDS Soc. 2014;17(4 Suppl 3):19565.
17. Woratanarat K, Kanjanabuch T, Suankratay C. Tenofovir disoproxil fumarate-associated nephrotoxicity in HIV-infected patients: a prospective controlled study. J Med Assoc Thai. 2013;96(4):432–9.
18. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461–70.
19. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation; classification; and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1–266.
20. Rodriguez-Nóvoa S, Alvarez E, Labarga P, Soriano V. Renal toxicity associated with tenofovir use. Expert Opin Drug Saf. 2010;9(4):545–59.
21. Ganesan A, Krantz EM, Huppler Hullsiek K, Riddle MS, Weintrob AC, Lalani T, et al. Determinants of incident chronic kidney disease and progression in a cohort of HIV-infected persons with unrestricted access to health care. HIV Med. 2013;14(2):65–76.
22. Scherzer R, Estrella M, Li Y, Deeks SG, Grunfeld C, Schlipak MG. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 2012;26(7):867–75.
23. Monteagudo-Chu MO, Chang MH, Fung HB, Bräu N. Renal toxicity of long-term therapy with tenofovir in HIV-infected patients. J Pharm Pract. 2012;25(5):552–9.
24. Madeddu G, Bonfanti P, De Socio GV, Carradori S, Grosso C, Marconi P, et al. Tenofovir renal safety in HIV-infected patients: results from the SCOLT Project. Biomed Pharmacother. 2008;62(1):6–11.
25. Mauss S, Berger F, Schmutz G. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS. 2005;19(1):93–5.
26. Wikman P, Safont P, Palacio M, Moreno A, Moreno S, Casado JL. The significance of antiretroviral-associated acute kidney injury in a cohort of ambulatory human immunodeficiency virus-infected patients. Nephrol Dial Transplant. 2013;28(8):2073–81.
27. Post FA, Campbell LJ, Hamzah L, Collins L, Jones R, Siwani R, et al. Predictors of renal outcome in HIV-associated nephropathy. Clin Infect Dis. 2008;46(8):1282–9.
28. Roe J, Campbell LJ, Ibrahim F, Hendry BM, Post FA. HIV care and the incidence of acute renal failure. Clin Infect Dis. 2008;47(2):242–9.
29. Ibrahim F, Hamzah L, Jones R, Nitsch D, Sabin C, Post F. Baseline kidney function as predictor of mortality and kidney disease progression in HIV-positive patients. Am J Kidney Dis. 2012;60(4):539–47.
30. Mulenga LB, Kruse G, Lakhi S, Cantrell RA, Reid SE, Zulu I, et al. Baseline renal insufficiency and risk of death among HIV-infected adults on antiretroviral therapy in Lusaka, Zambia. AIDS. 2008;22(14):1821–7.
31. Estrella MM, Parekh RS, Abraham A, Astor BC, Szczech LA, Anastos K, et al. The impact of kidney function at highly active antiretroviral therapy initiation on mortality in HIV-infected women. J Acquir Immune Defic Syndr. 2010;55(2):217–20.
32. Choi A, Scherzer R, Bacchetti P, Tien PC, Saag MS, Gibert CL, et al. Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons. Am J Kidney Dis. 2010;56(5):872–82.
33. Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, et al. Greater tenofovir associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis. 2008;197(1):102–8.
34. Kearney BP, Mathias A, Mittan A, Sayre J, Ebrahimi R, Cheng AK. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2006;43(3):278–83.
35. Kiser JJ, Carten ML, Aquilante CL, Anderson PL, Wolfe P, King TM, et al. Effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther. 2008;83(2):265–72.
36. Jullien V, Treluyer JM, Rey E, Jaffray P, Krivine A, Moachon L, et al. Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy. Antimicrob Agents Chemother. 2005;49(8):3361–6.
37. Kapadia J, Shah S, Desai C, Desai M, Patel S, Shah AN, et al. Tenofovir induced Fanconi syndrome: a possible pharmacokinetic interaction. Indian J Pharmacol. 2013;45(2):191–2.
38. Izzedine H, Hulot JS, Villard E, Goyenvalle C, Dominguez S, Ghosn J, et al. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis. 2006;194(11):1481–91.
39. Rodríguez-Novoa S, Labarga P, Soriano V, Egan D, Albalater M, Morello J, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis. 2009;48(11):e108–16.
40. Rodríguez-Novoa S, Labarga P, D’Avolio A, Barreiro P, Albalate M, Vispo E. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS. 2010;24(7):1064–6.
41. Fafin C, Pugliese P, Durant J, Mondain V, Rahelinirina V, De Salvador F, et al. Increased time exposure to tenofovir is associated with a greater decrease in estimated glomerular filtration rate in HIV patients with kidney function of less than 60 ml/min/1,73 m2. Nephron Clin Pract. 2012;120(4):c205–14.
42. Jülg BD, Bogner JR, Crispin A, Goebel FD. Progression of renal impairment under therapy with tenofovir. AIDS. 2005;19(12):1332–3.
43. Nelson M, Katlama C, Montaner J, Cooper D, Gazzard B, Clotet B, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS. 2007;21(10):1273–81.
44. Pradat P, Le Pogam MA, Okon JB, Trolliet P, Miailhes P, Brochier C, et al. Evolution of glomerular filtration rate in HIV-infected; HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate. J Viral Hepat. 2013;20(9):650–7.
45. Di Biagio A, Rosso R, Vitale F, Cardinale F, Sormani MP, Secondo G, et al. Risk factors for chronic kidney disease among human immunodeficiency virus-infected patients: a European case control study. Clin Nephrol. 2011;75(6):518–23.
46. Mallants R, Van Oosterwyck K, Van Vaeck L, Mols R, De Clercq E, Augustijins P. Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites. Xenobiotica. 2005;35(10–11):1055–66.
47. Miller D. Nucleoside phosphonate interactions with multiple organic anion transporters in renal proximal tubule. J Pharmacol Exp Ther. 2001;299(2):567–74.
48. Izzedine H, Launay-Vacher V, Deray G. Antiviral drug-induced nephrotoxicity. Am J Kidney Dis. 2005;45(5):804–17.